Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

Founded by the late Texan visionary energy magnate and philanthropist, the T. Boone Pickens Foundation is donating a substantial sum of $20 million to the Wilmer Eye Institute, part of Johns Hopkins Medicine. This significant donation, initially announced in 2013,…

Embarking on a career in ophthalmology involves a meticulous journey of education and training, with the residency period being a critical phase in shaping a future ophthalmologist’s expertise. The duration of an ophthalmology residency is a key consideration for aspiring…

In a significant stride towards advancing its clinical development program for ONS-5010, Outlook Therapeutics has received written agreement from the FDA under a special protocol assessment (SPA) for the NORSE EIGHT clinical trial protocol. This trial aims to evaluate the…

A team of investigators unveiled previously unknown inherited genetic variants associated with primary open-angle glaucoma (POAG), the most prevalent form of the disease. The study, based on the analysis of 11,275 individuals of African descent, sheds light on the genetic…

Ophthalmology Breaking News (OBN) is thrilled to present the first-ever interview with Dr. Filomena Ribeiro as the newly appointed President of the European Society of Cataract and Refractive Surgeons (ESCRS), effective January 1, 2024, succeeding Prof. Oliver Findl. Delve into…

Aviceda Therapeutics announced a significant milestone in the development of its lead ophthalmic candidate, AVD-104, with the enrollment of the first patient in the GLYCO phase 2 US clinical trial. The trial aims to evaluate the efficacy and safety of…
Leading the AI Ophthalmology Revolution Johns Hopkins Medicine Source: Author: | Date: 2024-01-08 08:00:00 Source: Author: | Date: 2024-01-08 08:00:00

In a recent announcement, Ocuphire Pharma disclosed that it has secured approval from the U.S. Food and Drug Administration (FDA) under a special protocol assessment (SPA) for the clinical trial protocol and planned statistical analysis of its LYNX-2 phase 3…

In a groundbreaking study published in The American Journal of Pathology, researchers at Mass Eye and Ear of the Harvard Medical School Department of Ophthalmology have unveiled a novel therapeutic approach using the neuropeptide α-melanocyte–stimulating hormone (α-MSH) to promote corneal…

Experiencing eye irritation after cataract surgery is not uncommon. While cataract surgery is generally safe and effective, it’s normal to experience some degree of discomfort in the postoperative phase. There can be several causes of eye irritation following the procedure.…